Zydus launches biosimilar for ophthalmic care
- IBEF
- February 20, 2026
Indian pharmaceutical company Zydus Lifesciences announced the launch of Anyra, India’s first biosimilar Aflibercept 2 mg developed in the country to address vision issues related to diseases like diabetic retinopathy and other retinal disorders. The move is significant in terms of improving domestic biologics capabilities and providing affordable and accessible high-end eye care solutions to the population of India. The country is home to 100 million people suffering from diabetes, and the launch of this biosimilar could be an attempt to cater to the growing demand for retinal disorders treatment in the country.
The new biosimilar is expected to increase the availability of eye care solutions to the masses by providing an affordable solution to the existing biologic drugs in the market. The move is expected to increase India’s position in the world biosimilar market as well as improve the country’s research capabilities in the pharmaceutical sector through indigenous innovation in biosimilar drug development. Zydus Lifesciences has also announced a deal with Regeneron and Bayer regarding the drug, which could be an attempt to increase international collaborations in the development of high-end therapeutics in the country. The move by Zydus Lifesciences is also an attempt by the company to increase the focus of Indian pharmaceutical companies on high-end biologics and specialty solutions that could increase the country’s position in the pharmaceutical sector in the coming years.
Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.
Partners
